secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001178913-25-002431
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion receives Nasdaq bid price deficiency notice; reverse split set for July 29
--------------------------------------------------------------------------------

- On July 18, 2025, Nasdaq notified Silexion that its ordinary shares' closing bid price was below $1.00 for 30 consecutive days.
- Bid price deficiency will be considered by Nasdaq hearings panel in continued listing decision.
- Shareholder-approved 1-for-15 reverse split effective after market close July 28; trading begins split-adjusted July 29.
- Company must also meet $2.5M minimum shareholders' equity by September 19, 2025 to maintain listing.
- Current trading of shares (SLXN) and warrants (SLXNW) unaffected at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002431/0001178913-25-002431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002431/zk2533462.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer